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Abstract
Background: Although use of complementary and alternative medicine (CAM) among cancer patients has been
described previously, prevalence of use has not commonly been compared to other disease groups in a true
population sample where CAM use or cancer is not the main focus. The aims of the present study are to (1)
examine how CAM use in cancer patients differs from people with a previous CHD diagnosis and people with no
cancer or CHD diagnosis in an unselected general population and (2), investigate the use of a CAM provider
among individuals with a previous cancer diagnosis.
Methods: A total of 8040 men and women aged 29 to 87 in the city of Tromsø, Norway filled in a questionnaire
developed specifically for the Tromsø V study with questions on life style and health issues. Visits to a CAM
provider within the last 12 months and information on cancer, heart attack and angina pectoris (heart cramp) were
among the questions. 1449 respondents were excluded from the analyses.
Results: Among the 6591 analysed respondents 331 had a prior cancer diagnosis, of whom 7.9% reported to have
seen a CAM provider within the last 12 months. This did not differ significantly from neither the CHD group (6.4%,
p = 0.402) nor the no cancer/CHD group (9.5%, p = 0.325).
Conclusion: According to this study, the proportion of cancer patients seeing a CAM provider was not statistically
significantly different from patients with CHD or individuals without cancer or CHD.
Background
Cancer patients’ self-reported use of complementary and
alternative medicine (CAM) is increasing, [1-3] although
studies report substantial differences in the level of use,
ranging from 7 [4] to 91% [5]. Younger, highly educated
women are the most frequent users [6-8]. Frequent use
is also reported among patients with symptoms and
symptom progression related to their cancer [9-13].
CAM treatment is mostly offered outside the national
health care service in Norway and paid out-of-pocket by
the patients. Prior to 2004 only physicians and dentists
could legally treat cancer patients [14]. The proportion
of cancer patients reporting CAM use in Norway varies
between 11.1 and 72% [15,16] depending on how CAM
is defined [15]. When defined as “at least one visit to a
CAM provider during the previous 12 months” the var-
iation narrows down to 16.1% [16] to 22.7% [15].
CAM use among cancer patients has rarely been
reported in an unselected general population sample,
and even more rarely been compared to use among
other patient groups in this type of sample [17].
Coronary heart disease (CHD) and cancer constituted
58% of all deaths in Norway in 2009 [18], and are the
two most common causes of death. In planning, admin-
istering and monitoring health care provisions, knowl-
edge about the choices and health care-related
behaviours made by these patient groups is important,
particularly the choices and behaviours related to treat-
ments outside the national health care service.
The magnitude of use of conventional health care in
CHD patients is well known. Few studies have, however,
examined CAM use in these patients, most of them in
highly selected population subgroups. Substantial * Correspondence: agnete.kristoffersen@uit.no
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85% [19-21] have been reported.
As with patients with other chronic diseases, CHD
patients are likely to use CAM to manage their condi-
tion, increase their quality of life, and prevent recur-
rence of disease [22,23]. So far, there are no comparable
data regarding use of CAM among Norwegian CHD
patients.
This wide range of reported CAM use in both cancer
and CHD patients may be due to several factors; differ-
ences in the definition of a CAM user [15,24,25],
whether CAM is used for general health purposes or for
illness-specific reasons [20,23], the time frame of
reported use [26] and differing legislation [27] regulating
CAM provisions and funding. The differences might
also be due to lack of population-based data on CAM
use in these two patient groups.
The aims of the present study are therefore to (1)
examine how CAM use in cancer patients differs from
people with a previous CHD diagnosis and people with
no cancer or CHD diagnosis in an unselected general
population and (2), investigate the use of a CAM provi-
der among individuals with a previous cancer diagnosis.
Methods
The Tromsø Study series (I-VI) are prospective studies
in the municipality of Tromsø, Northern Norway. The
design includes repeated population health surveys to
which total birth cohorts and random samples are
invited. This paper is based on data from the Tromsø V
study conducted in 2002.
A total of 10353 men and women were invited to par-
ticipate in this study. This included individuals partici-
pating in the extended fourth survey in 1994-1995
( T r o m s øI V )[ 2 8 ] .I na d d i t i o n ,a l li n h a b i t a n t sw h o
turned 30, 40, 45, 60 or 75 during 2001 were invited to
participate. As 2313 did not attend, the study included
8040 subjects, 4565 women and 3475 men, aged
between 29 and 87 (response rate 77.6%).
The Tromsø studies have been linked electronically to
the Cancer Registry of Norway (CRN) enabling the iden-
tification of cancer patients by two methods; through
self-reporting of cancer in the survey and through regis-
tration in the CRN. Registration of cancer has been
mandatory by law since 1952, and the registry is there-
fore considered virtually complete.
A total of 1280 participants had not answered the ques-
tion regarding visits to a CAM provider and were therefore
excluded from the current analysis. Further, 169 persons
were excluded due to the following two reasons: They had
experienced both cancer and CHD, or they had reported
having cancer without this being registered in the CRN
(Figure 1). The analysis of visits to a CAM provider in can-
cer and CHD patients thus included 6591 respondents.
The letter of invitation contained a questionnaire
developed specifically for the Tromsø study. Individuals
who attended the survey by undergoing a health screen-
ing and answering the first questionnaire received subse-
quently a second questionnaire that they were asked to
complete and return by mail.
The two questionnaires included questions on general
state of health, diseases suffered by the respondent or
their family, muscle pain and physical discomfort, food
habits, alcohol consumption, smoking habits, physical
activity in leisure time, level of education, use of medi-
cine and use of health services including a CAM provi-
der [29].
The question regarding visits to a CAM provider was
not directly related to any specific disease condition.
The questions concerning CAM and CHD were
included in the first questionnaire completed before the
health screening, while the question concerning cancer
was placed in the second questionnaire returned by mail
after the health screening.
A CAM user in this study is defined as a respondent
who checked one or more visits on the question: How
many visits have you made during the past year to an
alternative medical provider?A“no CAM user” is a
respondent who checked for no visits. This question was
one item in a list including 12 other non-CAM health
care providers (for example general practitioner (GP),
psychologist, psychiatrist, emergency room physician,
home nurse, physiotherapist, chiropractor, dentist etc.).
In Norway, an alternative medical provider is com-
monly understood by the public as a practitioner pro-
viding CAM both as alternative and complementary
treatment. A CAM provider offers therapies that are not
commonly offered within the public health care service
and are paid out-of-pocket by the patients themselves.
CAM use was compared between three groups:
1. The cancer group (n = 331)
2. The CHD group (n = 579)
3. The no cancer/CHD group (n = 5681)
The cancer group consisted of informants who had
checked Yes for: Have you ever had, or do you have can-
cer? and were registered with a cancer diagnosis in the
CRN. Informants were also included in this group if
they had left the question unanswered (due to deliberate
choice or failing to return the second questionnaire) but
were registered with a cancer diagnosis in the CRN.
Informants in this group were also required to have
checked No or have a missing value for both: Do you
have, or have you had a heart attack AND Do you have,
or have you had angina pectoris (heart cramp)?T h e
members of this group are referred to as “cancer
patients” even though the time of their clinical cancer
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considered themselves to be healed from their cancer.
The CHD group consisted of respondents who had
checked Yes for: Do you have, or have you had a heart
attack OR Do you have, or have you had angina pectoris
(heart cramp)? and who were not included in the cancer
group.
The no cancer/CHD group consisted of respondents
who had checked No or had a missing value for: Have
y o ue v e rh a d ,o rd oy o uh a v ec a n c e r ? ,a n dw e r enot
registered with cancer in the CRN nor were included in
the CHD group.
The primary endpoint in this study was reported visits
to a CAM provider over the previous 12 months in the
cancer group compared to the CHD group and the no
cancer/CHD group. The secondary endpoint was visits
to a CAM provider over the previous 12 months within
the cancer group.
Did not attend (n= 2313) 
Accepted invitation (n=8040) 
No cancer/CHD group 
(n=5681) 
No information on CAM use (n=1280) 
Self-reported cancer not confirmed in the 
CRN (n=83) 
Both cancer and CHD (n=39) 
Self-reported NO cancer, registrated with 
cancer in the CRN (n=47) 
 
Cancer group  
(n=331) 
Included (n=6591) 
Invited into the study (n=10353) 
Tromsø population (n=60086) 
CHD group  
(n=579) 
Figure 1 Flow chart that shows the selection of the studied population.
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0.05 we were able to report as statistically significant dif-
ferences in reported use of approximately 6.5 percentage
points between the two smallest groups.
The endpoints were analyzed using chi-square tests
and logistic regression in SPSS Windows (version 17.0,
SPSS Inc., Chicago, IL). When the compared groups dif-
fered significantly from each other in terms of baseline
characteristics with possible influence on CAM use, the
comparison between groups are also reported with
adjusted p-values.
The data inspectorate has been notified about the
study and the regional ethics committee has recom-
mended it.
Results
Basic characteristics of the studied participants
The cancer group consisted mainly of women, the CHD
group mainly of men, while the no cancer/CHD group
was gender-balanced. Individuals in the no cancer/CHD
group were higher educated than the cancer group and
the CHD group. The no cancer/CHD group had the
best self-reported health, the CHD group the poorest
(Table 1).
Mean time from first diagnosis was 9.6 years (median
= 6.6), ranging from 0 to 41 years in the cancer group,
and 9.6 years (median = 8) in the CHD group ranging
from 0 to 54.
Use of a CAM provider in the cancer group compared to
the CHD group
26 participants (7.9%) in the cancer group and 37 parti-
cipants (6.4%) in the CHD group had visited a CAM
provider within the last 12 months (p = 0.402, Figure 2).
The insignificant difference between the two groups
remains when adjusted for gender, age, self-reported
health and education.
Use of a CAM provider in the cancer group compared to
the no cancer/CHD group
593 participants (9.5%) in the no cancer/CHD group
and 26 participants in the cancer group (7.9%) had seen
a CAM provider the last 12 months (p = 0.325, Figure
2). 16 participants (4.8%) in the cancer group and 270
(4.3%) in the no cancer/CHD group had seen their pro-
vider more than three times (p = 0.209).
Use of a CAM provider within the cancer group
Among the 26 patients (7.9%) in the cancer group that
had visited a CAM provider in the previous 12 months,
10 patients had seen their provider one to three times
while 16 patients had visited a provider more than three
times.
A higher proportion of women compared to men
tended to have visited a CAM provider, 21 women
(10.6%) versus five men (3.8%) (p = 0.025). Of these,
both men and women were most likely to have visited a
provider more than three times.
Nine patients (11.5%) with metastases and 15 patients
(7.5%) with no metastases at first diagnosis had visited a
CAM provider in the previous 12 months (p = 0.287).
Eight patients (10.8%) with metastases and eight patients
without metastases (3.7%) had visited a CAM provider
more than three times.
16 patients (8.3%) with at least five years since first
diagnosis were just as likely to have visited a CAM pro-
vider as patients with one to five years since last diagno-
sis (9 patients, 8.3%). Only one person with less than
one year since last diagnosis had visited a CAM provider
within the last 12 months (2.9%).
Discussion
This study shows no significant difference in visits to a
CAM provider between population-based patients with
a prior cancer or CHD diagnosis, and also no statisti-
cally significant difference in visits to a CAM provider
between patients with a prior cancer diagnosis and indi-
viduals without cancer or CHD when adjusted for possi-
ble confounding factors. The findings can be seen as
contra intuitive, but are therefore possibly even more
important.
Bias considerations
The high response rate in this study ensures a represen-
tative sample of the population. There was a mismatch
between self-reported cancer and the registrations in the
CRN regarding 130 participants. They had either identi-
fied themselves as having had cancer without a
Table 1 Basic characteristics of studied participants
Cancer (n = 331) CHD (n = 579) No cancer/CHD (n = 5681)
Mean age, years (range) 66.6 (30-84) 68.9 (39-85) 57.12 (29-87)
Median age 67 69.5 60
Percentage of women 60.1% 36.1 55.0%
Years of education (mean) 9.9 9.1 11.2
Self-reported poor health 47.1 61.6% 32.8%
Living with a spouse/partner 68.1% 68.9% 73.2%
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themselves as having had no cancer with a confirmed
diagnosis in the CRN (n = 47). Possible reasons for this
may be (1) that the diagnosis had been uncertain and
therefore not confirmed in the CRN, (2) the respondent
had ticked off incorrectly in the questionnaire, (3) did
not remember their diagnosis as cancer or (4) forgot
about their previous cancer while filling in the
questionnaire.
The exclusion of patients denying actively a cancer
diagnosis despite a CRN registration can be seen as con-
troversial. None of these reported using CAM. If we had
included them in the cancer group, the proportion using
CAM in this group would therefore have been slightly
lower, while the differences would remain statistically
insignificant. It might also be controversial to include
patients with missing values on the CHD variable in the
cancer group when excluding patients with both cancer
and CHD. The number of cancer patients with a miss-
ing value on the CHD variables was seven, and none of
these reported to be CAM users. Excluding them in the
cancer group would only minimally have changed our
estimates, and none of the differences would reach sta-
tistical significance.
The questionnaire asked for the number of visits to a
CAM provider without defining aC A Mp r o v i d e r .T h i s
could constitute an over- or underreporting of visits
depending on how each participant defined a CAM pro-
vider. However, since the question regarding visits to a
CAM provider was listed among a number of other
health care providers, the separation between a CAM
provider and a conventional health care provider should
have been clear. There is no study in Norway on how the
public defines a CAM provider, but the most commonly
used CAM providers are massage therapists, acupunctur-
ists, reflexologists, spiritual healers and homeopaths [30].
Ac h i r o p r a c t o ri si nN o r w a yl i c e n s e db yt h eg o v e r n m e n t
as a regulated profession within conventional health care,
and is not seen or classified as a CAM provider. There is
n os t u d yi nN o r w a yo nh o wt h ep u b l i cd e f i n e saC A M
provider, but this possible misclassification is not likely
to be differential. The 12-month recall period concerning
use of a CAM provider might also result in inaccuracies
with regard to number of visits.
The onset of cancer or CHD might have occurred sev-
eral years ago and the patient might therefore have
given an inaccurate answer concerning whether or not
they have had the disease.
The potential misclassifications in this study are likely
to be non-differential and the results from this sample
a r et h e r e f o r eac o n s e r v a t i v ee s t i m a t eo fa n yp o p u l a t i o n
differences between groups.
 
Figure 2 Use of a CAM provider within the last 12 months. A comparison between the cancer group, the CHD group and the no cancer/
CHD group.
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pants are fully aware of the purpose of the study (CAM
use in cancer and CHD) was low in this study as this
was the purpose of this paper but not in any way the
main purpose of the Tromsø V study.
Other studies
CAM use in CHD populations
We have not succeeded in finding other studies report-
ing use of a “CAM provider“ among patients with CHD
and are therefore unable to present a direct comparison.
H o w e v e r ,aB r i t i s hs t u d yr e p o r t i n gu s eo f“any alterna-
tive or complementary therapies/medicines” reported
findings similar to ours (9.2%) [21]. The similar and
rather low CAM use in both studies might be due to
the fact that patients in neither study were given a defi-
nition of CAM or a pre-prepared list of CAM treat-
ments that might have added to the recall and produced
ah i g h e rr a t eo fC A Mu s e[ 3 1 ] .T h eB r i t i s hs t u d yh a da
wider definition of CAM but was, on the other hand,
administrated by a nurse in a hospital setting which
m i g h th a v em a d es o m ep a t i e n t sr e l u c t a n tt od i s c l o s e
CAM use.
CAM use in cancer patients
Comparison of our results with other studies in cancer
was also difficult since the variation in time frame of
u s e ,p u r p o s eo fu s e ,t i m es i n c ed i a g n o s i s ,d e f i n i t i o n so f
a CAM provider and the population studied, strongly
influence the results. We have therefore chosen to com-
pare our study to a limited selection of other studies
with focus on equality and comparability.
Breast cancer patients in England [32] and Canada
[33] had visited a CAM provider more often than
women with cancer in our study. This might be
explained by the fact that women with breast cancer are
generally more likely to be CAM users than patients
with cancer at other sites [34]. Since our study consisted
of all cancer sites, this might hamper the comparison.
These differences might also be explained by the limita-
tion of CAM use within the last 12 months in our
study, while long-term use of CAM was included in the
Canadian study.
A Norwegian study of CAM use in cancer patients
with a poor survival prognosis at the time of first diag-
nosis, found that 22.7% had seen a CAM provider at
least once after their diagnosis. They also found that the
reported use increased to 40.6% when CAM techniques
and over the counter (OTC) products were included
[15]. The rather higher use in that study might be due
to the longer time frame (since diagnosis) and the poor
prognosis [35].
Comparative studies
Our results are supported by lack of significant differ-
ences in use of a CAM provider between different
disease groups in a Canadian study. They compared
CAM use in patients with inflammatory bowel disease
(IBD), arthritis and a group with mixed chronic diseases
where a minority were cancer patients [36]. The sub-
stantially higher self-reported use in the Canadian study
(38.1%) might be due to the different nature of the dis-
eases studied and the different availability of adequate
curative and/or palliative treatment within the health
care system. The fact that our study is a population-
based and not a study limited to patients with the con-
dition under study or to CAM use in general, might
also explain some of the differences.
Similar use of a CAM provider in a cancer and a no
cancer group was found in a US study conducted in
2002 [37]. Their study was like ours mainly based on
long-term cancer survivors which might explain the
similarities between the two groups. They found, how-
ever, that reported CAM use was higher in the cancer
group when non-prayer CAM services, products, and
practices were included.
It is not unlikely that the similar use of a CAM provi-
der in the cancer group and the no cancer/CHD group
in our study partly could be due to the strict legislation
that regulated the CAM field at the time of the study;
only physicians and dentists were allowed to treat can-
cer patients. It is therefore possible that the reported
use was, at least partly, connected to other health pro-
blems than treating the cancer.
Cancer patients in our study visited a CAM provider
less frequently than cancer patients in the USA [17].
Contrary to our results, the US-study found that cancer
patients were more likely to use a CAM provider than
the general population and individuals with chronic ser-
ious diseases, including CHD [17]. The higher use might
be due to different definitions of a CAM provider and
the legal restrictions on CAM treatment of cancer in
Norway [38].
Cancer patients in our study also used a CAM provi-
der less than Norwegian cancer patients in a similar
study conducted in Nord-Trøndelag, Central Norway in
1995-1997 (HUNT) [16](8.2% versus 16.1%). They
found, contrary to us, that cancer patients were more
likely to have seen a CAM provider than the total popu-
lation. Possible reasons for the higher use might be that
the availability of CAM providers is higher in their area.
And possibly more important, in the HUNT study they
listed several commonly used CAM providers as a
reminder for the patients in the questionnaire. This
might have improved the recall and made it easier to
understand what the researchers were asking for [31,39].
They also included chiropractors in their definition of a
CAM provider which is specifically excluded in our
study as they are licensed health care personnel in Nor-
way; if visits to a chiropractor were included in our
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10.9% in the cancer group.
T h er a t h e rl o wu s eo faC A Mp r o v i d e ri na l lg r o u p s
compared to studies from other countries shows how
important it is to do domestic, locally-based studies.
The observed low use might be due to cost differences
in Norway. While most treatments offered within the
public health care service are free of charge, most CAM
treatments are paid out-of pocket.
Interpretation
This is the first population-based study that to our
k n o w l e d g er e p o r t su s eo faC A Mp r o v i d e ri nC H D
patients and is therefore a door-opener to the field. In
research regarding use of CAM in cancer patients, it is
important to make comparisons with other relevant
chronic disease groups. The differences and similarities
found might contribute to a better understanding of the
needs of the different groups. In addition, our study can
inspire further research in the field.
K n o w l e d g eo fC A Mu s ei nd i f f e r e n tp a t i e n tg r o u p si s
important for the conventional medical community. It is
therefore important that they ask their patients about
CAM use as negative interactions between conventional
and CAM treatments can occur. The number of CAM
users are likely to be higher than what was found here if
OTC products and self-help techniques were included
in the study [26].
Our study contributes to the information needed for
health care providers and politicians to make knowl-
edge-based decisions concerning CAM use. Our results
differ from those from other countries, supporting the
importance of locally performed surveys. However, this
possible interpretation must be drawn with caution, as
worldwide experience and knowledge give a broader
perspective for creating guidelines and political
priorities.
Studies like ours contribute to a broader knowledge
base regarding cancer patients’ attitudes to, and experi-
ence with, use of a CAM provider. This is needed to
balance the impressions from random magazine reports
and/or prejudiced points of view obtained from strong
believers or opponents of CAM. The assumed wide-
spread use of CAM among cancer patients is not docu-
mented in our results.
Conclusions
The proportion of cancer patients in the Tromsø V
study that visited a CAM provider was not statistically
significantly different from patients with CHD or indivi-
duals without cancer or CHD. These findings are in
accordance with some studies and contrary to others.
Most other studies report a higher use of a CAM provi-
der than we found in our study.
This study indicates that locally based contextual sur-
veys are necessary to make scientific and political deci-
sions from a knowledge-based point of view.
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